This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Goldstein, E. J. C.
Right arrow Articles by Tyrrell, K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Goldstein, E. J. C.
Right arrow Articles by Tyrrell, K.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, October 2000, p. 2747-2751, Vol. 44, No. 10
0066-4804/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.

Comparative In Vitro Activities of GAR-936 against Aerobic and Anaerobic Animal and Human Bite Wound Pathogens

Ellie J. C. Goldstein,1,2,* Diane M. Citron,1 C. Vreni Merriam,1 Yumi Warren,1 and Kerin Tyrrell1

R. M. Alden Research Laboratory, Santa Monica-UCLA Medical Center, Santa Monica, California 90404,1 and UCLA School of Medicine, Los Angeles, California 900732

Received 12 May 2000/Accepted 11 July 2000

GAR-936 is a new semisynthetic glycylcycline with a broad antibacterial spectrum, including tetracycline-resistant strains. The in vitro activities of GAR-936, minocycline, doxycycline, tetracycline, moxifloxacin, penicillin G, and erythromycin were determined by agar dilution methods against 268 aerobic and 148 anaerobic strains of bacteria (including Pasteurella, Eikenella, Moraxella, Bergeyella, Neisseria, EF-4, Bacteroides, Prevotella, Porphyromonas, Fusobacterium, Staphylococcus, Streptococcus, Enterococcus, Corynebacterium, Propionibacterium, Peptostreptococcus, and Actinomyces) isolated from infected human and animal bite wounds in humans, including strains resistant to commonly used antimicrobials. GAR-936 was very active, with an MIC at which 90% of the strains are inhibited (MIC90) of <= 0.25 µg/ml, against all aerobic gram-positive and -negative strains, including tetracycline-resistant strains of Enterococcus, Streptococcus, and coagulase-negative staphylococci, except for Eikenella corrodens (MIC90, <= 4 µg/ml). GAR-936 was also very active against all anaerobic species, including tetracycline-, doxycycline-, and minocycline-resistant strains of Prevotella spp., Porphyromonas spp., Bacteroides tectum, and Peptostreptococcus spp., with an MIC90 of <= 0.25 µg/ml. Erythromycin- and moxifloxacin-resistant fusobacteria were susceptible to GAR-936, with an MIC90 of 0.06 µg/ml.

* Corresponding author. Mailing address: 2021 Santa Monica Blvd., Suite 640 East, Santa Monica, CA 90404. Phone: (310) 315-1511. Fax: (310) 315-3662. E-mail: EJCGMD{at}aol.com.

Antimicrobial Agents and Chemotherapy, October 2000, p. 2747-2751, Vol. 44, No. 10
0066-4804/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.


This article has been cited by other articles:

  • Salas, C., Calvo, J., Martinez-Martinez, L. (2008). Activity of Tigecycline against Coryneform Bacteria of Clinical Interest and Listeria monocytogenes. Antimicrob. Agents Chemother. 52: 1503-1505 [Abstract] [Full Text]  
  • Brown, S. D., Traczewski, M. M. (2007). Comparative In Vitro Antimicrobial Activity of Tigecycline, a New Glycylcycline Compound, in Freshly Prepared Medium and Quality Control. J. Clin. Microbiol. 45: 2173-2179 [Abstract] [Full Text]  
  • Goldstein, E. J. C., Citron, D. M., Merriam, C. V., Warren, Y. A., Tyrrell, K. L., Fernandez, H. T. (2006). Comparative In Vitro Susceptibilities of 396 Unusual Anaerobic Strains to Tigecycline and Eight Other Antimicrobial Agents. Antimicrob. Agents Chemother. 50: 3507-3513 [Abstract] [Full Text]  
  • Kasbekar, N. (2006). Tigecycline: A new glycylcycline antimicrobial agent.. Am J Health Syst Pharm 63: 1235-1243 [Abstract] [Full Text]  
  • Noel, A. R., Bowker, K. E., MacGowan, A. P. (2005). Pharmacodynamics of Moxifloxacin against Anaerobes Studied in an In Vitro Pharmacokinetic Model. Antimicrob. Agents Chemother. 49: 4234-4239 [Abstract] [Full Text]  
  • Pankey, G. A. (2005). Tigecycline. J Antimicrob Chemother 56: 470-480 [Abstract] [Full Text]  
  • Yin, L.-Y., Lazzarini, L., Li, F., Stevens, C. M., Calhoun, J. H. (2005). Comparative evaluation of tigecycline and vancomycin, with and without rifampicin, in the treatment of methicillin-resistant Staphylococcus aureus experimental osteomyelitis in a rabbit model. J Antimicrob Chemother 55: 995-1002 [Abstract] [Full Text]  
  • Livermore, D. M., Sefton, A. M., Scott, G. M. (2003). Properties and potential of ertapenem. J Antimicrob Chemother 52: 331-344 [Abstract] [Full Text]  
  • Cercenado, E., Cercenado, S., Bouza, E. (2003). In Vitro Activities of Tigecycline (GAR-936) and 12 Other Antimicrobial Agents against 90 Eikenella corrodens Clinical Isolates. Antimicrob. Agents Chemother. 47: 2644-2645 [Abstract] [Full Text]  
  • Brooke, C. J., Hampson, D. J., Riley, T. V. (2003). In Vitro Antimicrobial Susceptibility of Brachyspira pilosicoli Isolates from Humans. Antimicrob. Agents Chemother. 47: 2354-2357 [Abstract] [Full Text]  
  • Lefort, A., Lafaurie, M., Massias, L., Petegnief, Y., Saleh-Mghir, A., Muller-Serieys, C., Le Guludec, D., Fantin, B. (2003). Activity and Diffusion of Tigecycline (GAR-936) in Experimental Enterococcal Endocarditis. Antimicrob. Agents Chemother. 47: 216-222 [Abstract] [Full Text]  
  • Milatovic, D., Schmitz, F.-J., Verhoef, J., Fluit, A. C. (2003). Activities of the Glycylcycline Tigecycline (GAR-936) against 1,924 Recent European Clinical Bacterial Isolates. Antimicrob. Agents Chemother. 47: 400-404 [Abstract] [Full Text]  
  • Wallace, R. J. Jr., Brown-Elliott, B. A., Crist, C. J., Mann, L., Wilson, R. W. (2002). Comparison of the In Vitro Activity of the Glycylcycline Tigecycline (Formerly GAR-936) with Those of Tetracycline, Minocycline, and Doxycycline against Isolates of Nontuberculous Mycobacteria. Antimicrob. Agents Chemother. 46: 3164-3167 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»